Immutep Ltd ADR (IMMP) Stock Price, Quote & News

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 2 8315 7003

Fax: 61 2 8569 1880

Website: www.immutep.com

Address:

Australia Square, Level 32 264 George Street, Sydney, Australia

LetsgoDudeszi Mar. 21 at 7:42 PM

$IMMP why nobody selling

0 · Reply

Pennytwits Mar. 21 at 6:51 PM

$IMMP what good is a lot of cash with no income

0 · Reply

BandG Mar. 21 at 5:01 PM

$IMMP For any on the stock... Buy now to lower the medium price

0 · Reply

MrMaxxxx Mar. 20 at 11:01 PM

$IMMP Me like. Too many 🤡🤡🤡 On this board. I.keep sending them To my Iggyworld. 😆🤣🤣😂🤣🤣

0 · Reply

Messerschmittbf109 Mar. 20 at 9:18 PM

$IMMP and so ….

0 · Reply

LetsgoDudeszi Mar. 20 at 8:21 PM

$IMMP what happend why nobody shorted

0 · Reply

BioTechBling Mar. 20 at 5:31 PM

$IMMP Horrible leader-less ship (see my previous posts). Move to SLS with upcoming AML cure to recover from IMMP lemmings gravity reality. Not sure why I bother, but I was in your shoes before realizing even active Efti cannot overcome leader-less-ship…

0 · Reply

ToRni27 Mar. 20 at 5:11 PM

$IMMP 0

0 · Reply

BullBobo Mar. 20 at 4:48 PM

$IMMP

0 · Reply

BullBobo Mar. 20 at 4:48 PM

$IMMP Buying for cheap..wayy too strong of a pipeline for to justify the this stock price. They have >90 mn in cash and a runway till 2028

0 · Reply

IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm

Thu, 19 Mar 2026 15:07:00 -0400 - 2 days ago

IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Thu, 19 Mar 2026 10:00:00 -0400 - 2 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

Wed, 18 Mar 2026 17:28:00 -0400 - 3 days ago

IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Trial Progress: Levi & Korsinsky

Wed, 18 Mar 2026 15:02:00 -0400 - 3 days ago

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Tue, 17 Mar 2026 18:14:00 -0400 - 4 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

Tue, 17 Mar 2026 15:15:00 -0400 - 4 days ago

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation – IMMP

Tue, 17 Mar 2026 11:46:00 -0400 - 4 days ago

Ongoing Investigation into Immutep Limited (IMMP): Contact Levi & Korsinsky About Potential Fraud

Mon, 16 Mar 2026 08:03:00 -0400 - 5 days ago

Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-03-13T17:23:35.000Z - 8 days ago

Immutep Stock Tanks After Futility Analysis Ends Key Lung Cancer Trial Early

2026-03-13T07:28:36.000Z - 8 days ago

Immutep Discontinues Phase III Trial Of Eftilagimod Alfa In First-Line NSCLC; Stock Drops

Fri, 06 Feb 2026 08:00:00 -0500 - 6 weeks ago

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Thu, 29 Jan 2026 08:00:00 -0500 - 7 weeks ago

Immutep Quarterly Activities Report Q2 FY26

Mon, 22 Dec 2025 08:00:00 -0500 - 3 months ago

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

Mon, 08 Dec 2025 02:34:15 -0500 - 3 months ago

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

2025-12-08T07:28:15.000Z - 3 months ago

Dr. Reddy’s Laboratories enters strategic collaboration with Immutep SAS for exclusive licensing of eftilagimod alfa

Mon, 20 Oct 2025 08:01:00 -0400 - 5 months ago

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Mon, 08 Sep 2025 08:00:00 -0400 - 6 months ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Wed, 30 Jul 2025 08:00:00 -0400 - 8 months ago

Immutep Quarterly Activities Report Q4 FY25

Tue, 29 Jul 2025 08:00:00 -0400 - 8 months ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Tue, 27 May 2025 08:00:00 -0400 - 10 months ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Thu, 15 May 2025 15:50:04 -0400 - 11 months ago

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

Thu, 08 May 2025 08:46:59 -0400 - 11 months ago

Immutep Limited: Surging On Positive Head And Neck Data

Wed, 02 Apr 2025 08:00:00 -0400 - 1 year ago

Immutep to Participate in Upcoming Investor Conferences

Fri, 31 Jan 2025 08:00:00 -0500 - 1 year ago

Immutep Quarterly Activities Report Q2 FY25

Tue, 28 Jan 2025 16:37:29 -0500 - 1 year ago

Immutep Limited: Continuing To Make The Case For Eftilagimod

Tue, 17 Dec 2024 08:00:00 -0500 - 1 year ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Thu, 12 Dec 2024 08:15:00 -0500 - 1 year ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Fri, 15 Nov 2024 15:18:16 -0500 - 1 year ago

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Thu, 14 Nov 2024 11:16:11 -0500 - 1 year ago

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Thu, 14 Nov 2024 08:15:00 -0500 - 1 year ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Tue, 29 Oct 2024 08:00:00 -0400 - 1 year ago

Immutep Quarterly Activities Report Q1 FY25

Thu, 10 Oct 2024 08:00:00 -0400 - 1 year ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Mon, 07 Oct 2024 09:10:11 -0400 - 1 year ago

Immutep: Navigating The Bumps In The Road

Mon, 16 Sep 2024 08:00:00 -0400 - 1 year ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

2024-09-14T11:19:07.000Z - 1 year ago

Immutep Ltd Clinical Results Webinar Transcript

2024-09-14T11:19:05.000Z - 1 year ago

Immutep Ltd Webcast Presentation Transcript

Wed, 31 Jul 2024 08:00:00 -0400 - 1 year ago

Immutep Quarterly Activities Report Q4 FY24

Mon, 15 Jul 2024 13:54:02 -0400 - 1 year ago

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Thu, 11 Jul 2024 18:40:00 -0400 - 1 year ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Wed, 03 Jul 2024 08:00:00 -0400 - 1 year ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Tue, 25 Jun 2024 08:00:00 -0400 - 1 year ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Wed, 05 Jun 2024 06:00:00 -0400 - 1 year ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

Sun, 02 Jun 2024 20:38:00 -0400 - 1 year ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Wed, 15 May 2024 08:00:00 -0400 - 2 years ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Thu, 02 May 2024 08:00:00 -0400 - 2 years ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Wed, 01 May 2024 12:39:01 -0400 - 2 years ago

Immutep: Realizing The Expected Catalysts, With More To Come

Mon, 29 Apr 2024 08:00:00 -0400 - 2 years ago

Immutep Quarterly Activities Report Q3 FY24

Wed, 24 Apr 2024 08:00:00 -0400 - 2 years ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Thu, 18 Apr 2024 08:00:00 -0400 - 2 years ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Mar 5, 2024, 8:00 AM EST - 2 years ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Jan 30, 2024, 8:00 AM EST - 2 years ago

Immutep Quarterly Activities Report Q2 FY24

Jan 4, 2024, 8:00 AM EST - 2 years ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Jan 3, 2024, 5:04 PM EST - 2 years ago

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Dec 21, 2023, 8:00 AM EST - 2 years ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Dec 7, 2023, 8:00 AM EST - 2 years ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Nov 22, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 9, 2023, 8:00 AM EST - 2 years ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Nov 6, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

LetsgoDudeszi Mar. 21 at 7:42 PM

$IMMP why nobody selling

0 · Reply

Pennytwits Mar. 21 at 6:51 PM

$IMMP what good is a lot of cash with no income

0 · Reply

BandG Mar. 21 at 5:01 PM

$IMMP For any on the stock... Buy now to lower the medium price

0 · Reply

MrMaxxxx Mar. 20 at 11:01 PM

$IMMP Me like. Too many 🤡🤡🤡 On this board. I.keep sending them To my Iggyworld. 😆🤣🤣😂🤣🤣

0 · Reply

Messerschmittbf109 Mar. 20 at 9:18 PM

$IMMP and so ….

0 · Reply

LetsgoDudeszi Mar. 20 at 8:21 PM

$IMMP what happend why nobody shorted

0 · Reply

BioTechBling Mar. 20 at 5:31 PM

0 · Reply

ToRni27 Mar. 20 at 5:11 PM

$IMMP 0

0 · Reply

BullBobo Mar. 20 at 4:48 PM

$IMMP

0 · Reply

BullBobo Mar. 20 at 4:48 PM

$IMMP Buying for cheap..wayy too strong of a pipeline for to justify the this stock price. They have >90 mn in cash and a runway till 2028

0 · Reply

Messerschmittbf109 Mar. 20 at 4:13 PM

$IMMP I almost 20 years …and repeat only ephemeral joys of a few hours I went out months ago never a joy

0 · Reply

eddy1 Mar. 20 at 3:58 PM

$IMMP is anyone out there optimistic about the stock I’ve been holding it for over six years

2 · Reply

ckruel Mar. 20 at 2:39 PM

$IMMP https://tipranks.onelink.me/WJho/cqf4acqz

0 · Reply

rispi Mar. 20 at 1:48 PM

$IMMP pumpers got what they deserve.

0 · Reply

Jurek13 Mar. 20 at 1:33 PM

$IMMP

0 · Reply

LarryFin Mar. 20 at 12:59 PM

$IMMP The stock is dead - only sideways movement without volumen - i am out - bye bye

1 · Reply

BullBobo Mar. 19 at 11:28 PM

$IMMP Let that mark the onset of the green wave

0 · Reply

BioTechBling Mar. 19 at 9:03 PM

$IMMP CRAZY that my prior post has no traction here… SLS w/ LANDMARK AML CURE expected to >10X in 2026 from soon to be positive Phase 3 Regal trial while leader-less-ship IMMP burns remaining $ and hope in phase 1… 2026 Winners are in SLS, a rare stock going up today despite current market turbulence.. You do you…

0 · Reply

Messerschmittbf109 Mar. 19 at 7:55 PM

$IMMP Insignia Financial Ceases to Be Substantial Holder in Immutep Story Highlights Insignia Financial and its subsidiaries have ceased to be a substantial shareholder in Immutep as of 13 March 2026. A series of on-market trades by Insignia-related entities reduced their stake below the reportable threshold, modestly reshaping Immutep’s institutional ownership profile.

0 · Reply

eddy1 Mar. 19 at 7:54 PM

$IMMP 21000 shares

0 · Reply

Jurek13 Mar. 19 at 7:23 PM

$IMMP short noobs attack

0 · Reply

eddy1 Mar. 19 at 7:05 PM

$IMMP I’ve been praying with this stock forever

0 · Reply

Market Cap	61.23M
Revenue (ttm)	6.69M
Net Income (ttm)	-39.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-594.62%
Debt to Equity Ratio	0.01

Volume	1,439,200
Avg Vol	1,421,670
Day's Range	N/A - N/A
Shares Out	147.37M
Stochastic %K	1%
Beta	1.77
Analysts	Sell
Price Target	$1.00